drugset / Trial / NCT06752408
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
Phase 2
Not yet recruiting
316 enrolled
Peking Union Medical College Hospital
China-Japan Friendship Hospital · collabPeking University People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open-label, non-inferiority real world study. The study is designed to evaluate the efficacy and safety of Aumolertinib versus Osimertinib in the first-line treatment of patients with EGFR mutated locally advanced or metastatic non-small-cell lung cancer.
Timeline
- Start
- 2024-12-17
- Primary completion
- 2027-01-16
- Completion
- 2028-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | 110 mg | Oral |
| Comparator | Osimertinib | Small molecule | 80 mg | Oral |